Efforts to standardize bioanalytical method validation (BMV) for both non-clinical and clinical studies are crucial in today’s pharmaceutical landscape. As drug development becomes increasingly complex, the significance of pharmacokinetics characterization in assessing drug safety and efficacy has intensified. This shift highlights the need for clear guidance that ensures the accuracy and reproducibility of bioanalytical data.
Historical Context
For over 25 years, bioanalytical scientists and practitioners have played a vital role in shaping bioanalysis procedures and standards. This collaborative effort gained momentum through the American Association of Pharmaceutical Scientists (AAPS)/FDA ‘Crystal City’ workshops, which fostered dialogue between regulatory bodies and industry experts.
During this time, various regulatory agencies, including the FDA, the European Medicines Agency, and others from Japan, Brazil, and China, issued guidelines on BMV. Although these guidelines share a common goal of producing reliable and reproducible standards, the existence of multiple documents has led to inconsistencies. Variations in interpretation and application of these standards have created ambiguity, posing challenges for drug manufacturers during the global approval process.
The Emergence of ICH M10
In 2016, the International Council for Harmonization (ICH) recognized the need for a unified guideline for BMV. Responding to this opportunity, representatives from AAPS, the European Bioanalysis Forum (EBF), and the Japan Bioanalysis Forum (JBF) collaborated to draft a proposal for bioanalytical harmonization. This proposal was submitted to the European Federation of Pharmaceutical Industries and Associations (EFPIA) for consideration by the ICH assembly.
The ICH assembly endorsed the proposal, leading to the formation of an Informal Working Group tasked with drafting a business plan and concept paper for BMV harmonization. By October 2016, the ICH Assembly officially recognized BMV as a new multidisciplinary topic for harmonization, known as ICH M10.
Collaborative Efforts
With the initiation of the ICH process, the three-region team focused on understanding the workings of the ICH and ensuring effective representation in the Expert Working Group (EWG). The team emphasized the need for industry input early in the process, as many companies supporting regulated studies lacked direct representation in ICH discussions.
To facilitate this input, the team organized workshops in the United States and Europe in September 2017. These workshops attracted a global audience and were designed to address areas of expected consensus and current concerns that required harmonization. The U.S. workshop prioritized strategic discussions, while the European workshop centered on sharing survey data regarding industry practices and experiences.
Continuing Collaboration
The partnership between AAPS, EBF, and JBF has proven vital in addressing the objectives of the ICH harmonization process. Their ongoing collaboration aims to enhance the efficiency of drug development while ensuring that safety and efficacy evaluations remain uncompromised. These efforts are critical as the pharmaceutical industry navigates the complexities of regulatory compliance and strives for innovation.
Takeaway Insights
- The standardization of bioanalytical method validation is essential for efficient drug development.
- Historical workshops have significantly influenced bioanalysis procedures and standards.
-
ICH M10 represents a concerted effort to harmonize BMV across multiple regulatory frameworks.
-
Early industry engagement in the ICH process can lead to more effective guidelines.
-
Continued collaboration among industry stakeholders is crucial for achieving harmonization goals.
In conclusion, the journey toward harmonizing bioanalytical method validation through ICH M10 underscores the importance of collaboration in the pharmaceutical industry. By fostering open communication and sharing insights, stakeholders can navigate regulatory challenges more effectively, ultimately benefiting drug development and public health.
Read more → www.pharmtech.com